Stock listing

LSE:0QN1 Santhera Pharmaceuticals Holding AG Share Price

UK listing (LSE) of Santhera Pharmaceuticals Holding AG · home listing SIX Swiss:SANN

Follow Santhera Pharmaceuticals Holding AG into a list and get an email when it puts out news.

Share price · LSE:0QN1

14.94 CHF +0.32 (+2.2%)

Close on Oct 27, 2026

Day range
14.58 – 14.98 CHFOct 27, 2026
Volume
1,793 sharesOct 27, 2026
Market cap
207.0M CHFAt the close on Oct 27, 2026 · price × 13.85M shares outstanding
Santhera Pharmaceuticals Holding AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:SANN · Home15.20 CHF+0.16 (+1.1%)63,94714.9015.4014.7815.04Close on Nov 3, 2026
LSE:0QN114.94 CHF+0.32 (+2.2%)1,79314.5814.9814.5814.62Close on Oct 27, 2026
Ticker
LSE:0QN1
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
LSE
Currency
CHF

What changed lately

Calls

Replays

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q2 2026 Earnings Call

    Wed, Sep 30, 2026 · 8:00 AM ET

    Watch Transcript

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q4 2025 Earnings Call

    Tue, Apr 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Santhera Pharmaceuticals Holding (SIX Swiss: SANN) Q2 2025 Earnings Call

    Tue, Sep 23, 2025 · 8:00 AM ET

    Watch Transcript

Latest news

Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea

Oct 23, 2026

Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

Jul 13, 2026

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

Jun 2, 2026

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Apr 30, 2026

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

Apr 28, 2026

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

Apr 28, 2026

Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

Apr 27, 2026

Santhera Appoints Orlando Oliveira as Chief Executive Officer

Apr 23, 2026

Full Year 2025 Trading Update

Mar 12, 2026

Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

Mar 10, 2026

All Santhera Pharmaceuticals Holding AG news

Decks

Santhera Pharmaceuticals Holding AG on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
18 in the last 12 months · 34 in all · newest Oct 23, 2026 · oldest 2025
Calls
4 calls with a replay · 4 with a transcript · latest Sep 30, 2026
Decks
18 decks · latest October 2026

Where Santhera Pharmaceuticals Holding AG is listed

ListingExchangeCountryCurrency
SIX Swiss:SANN · Home listingSIX SwissSwitzerlandCHF
OTC:SPHDFOTCUnited StatesUSD
LSE:0QN1 · This pageLSEUnited KingdomCHF
gettex:S3F0gettexGermanyEUR
LS Exchange:A3EJMQLS ExchangeGermanyEUR
Lang & Schwarz:A3EJMQLang & SchwarzGermanyEUR
Aquis:SANNZAquisUnited KingdomCHF
BX Swiss:S3F0BX SwissSwitzerlandCHF
Tradegate:S3F0TradegateGermanyEUR
Dusseldorf:S3F0DusseldorfGermanyEUR
Frankfurt:S3F0FrankfurtGermanyEUR
Hamburg:S3F0HamburgGermanyEUR
Munich:S3F0MunichGermanyEUR
Stuttgart:S3F0StuttgartGermanyEUR
Turquoise:SANNZTurquoiseUnited KingdomCHF

Log in to ask 6ix AI your own questions about Santhera Pharmaceuticals Holding AG.